next agonist
The middle-ground agonist already exists. You just can't have it.
Here is the fact that reframes the entire Melanotan story: a safe-enough, approved, MC1R-targeted photoprotective drug already made it to market. It’s called afamelanotide, sold as Scenesse — and it is chemically Melanotan I, the original Arizona peptide, developed properly over three decades.
The EU approved it in 2014 and the FDA followed in 2019. It’s a real medicine with real trials behind it. And virtually no one can get it.
Why it’s locked away
Afamelanotide is approved only for erythropoietic protoporphyria (EPP), a rare genetic disorder in which light exposure causes searing pain. For EPP patients the benefit-risk math was clear, the patient population was small and desperate, and the regulatory pathway was tractable. The drug ships as a subcutaneous implant administered in specialty clinics at rare-disease prices.
That’s the pattern worth understanding: the molecule cleared the bar. The indication is what’s narrow. Getting from “treats a rare light-sensitivity disease” to “reduces sun damage for the general fair-skinned public” isn’t a chemistry problem — it’s a trials-economics problem, and a brutal one:
The endpoint is slow and expensive. Proving a drug prevents skin cancer in healthy people means enrolling enormous cohorts and following them for years. Compare that to EPP, where the endpoint — pain-free time in light — shows up in months.
The risk tolerance flips. A drug for healthy people gets held to a far stricter safety standard than a drug for a painful disease with no alternatives. Long-term melanocortin stimulation in millions of healthy users raises questions — including the mole-surveillance question from the gray-market era — that a rare-disease program never had to answer at scale.
The delivery format is wrong for mass adoption. Clinic-administered implants work for a rare disease. A consumer photoprotective would need something closer to a monthly pen or better.
The GLP-1 parallel, taken seriously
The hope animating this site is that photoprotection gets its GLP-1 moment, and the analogy is more structural than it first appears. GLP-1 drugs were peptides confined for years to a “worthy” medical indication (diabetes) while the larger adjacent demand (weight) went unserved or was served by a sketchy supplement-and-gray-market fringe. What broke the dam was a combination the melanocortin field hasn’t yet assembled: outcome trials big enough to satisfy regulators for a broad population, delivery engineering that made self-administration routine, and a commercial thesis that the lifestyle-adjacent market was worth pharmaceutical-scale investment.
Every one of those pieces is conceivable for an MC1R-selective agent. None currently exists. Selectivity chemistry has advanced since MT-II’s shotgun days; sunscreen’s compliance failure is well documented; melanoma incidence gives the public-health case. What’s missing is a sponsor willing to fund the decade-long prevention trial — and possibly an intermediate indication (high-risk patients, transplant recipients, xeroderma-adjacent populations) that could serve as the beachhead the way diabetes did for GLP-1.
Labeled hopium
Call this what it is: hope, with a mechanism sketch attached. There is no announced program, as of this writing, racing toward a general-population photoprotective agonist, and readers should treat any product claiming to be that — today, in a vial, from a website — as the cautionary tale section of this site, not this section. The honest position is the uncomfortable one: the science looks feasible, the demand is provably real, and the gap is institutional. Gaps like that do eventually close. GLP-1 proved it. This site is here to watch, and report straight, if this one does.